Short Interest in Check-Cap Ltd (NASDAQ:MBAI) Decreases By 71.9%

Check-Cap Ltd (NASDAQ:MBAI) was the target of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 26,875 shares, a decrease of 71.9% from the July 30th total of 95,679 shares. Based on an average daily volume of 27,346 shares, the days-to-cover ratio is presently 1.0 days. Currently, 2.0% of the shares of the company are short sold.

Check-Cap Stock Up 0.2%

NASDAQ MBAI traded up $0.01 during trading hours on Friday, hitting $6.58. 35,021 shares of the stock were exchanged, compared to its average volume of 19,266. The company has a market cap of $9.08 million, a price-to-earnings ratio of -0.47 and a beta of 0.68. Check-Cap has a 12-month low of $4.41 and a 12-month high of $27.44. The stock has a 50-day moving average of $8.09 and a 200 day moving average of $10.38.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Check-Cap Company Profile

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.